NASDAQ:MLND

Millendo Therapeutics Stock Forecast, Price & News

$1.51

-0.11 (-6.79 %)

(As of 10/27/2020 12:00 AM ET)

Add

Compare

Today's Range

$1.43

Now: $1.51▼

$1.64

50-Day Range

$1.51

MA: $1.63▼

$1.83

52-Week Range

$1.26

Now: $1.51▼

$9.88

Volume739,152 shs

Average Volume791,666 shs

Market Capitalization$28.69 million

P/E RatioN/A

Dividend YieldN/A

Beta1.19

Millendo Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing novel treatments for orphan endocrine diseases in the United States. Its lead product candidates include livoletide, a potential treatment for Prader-Willi syndrome; nevanimibe, a potential treatment for patients with classic congenital adrenal hyperplasia; and MLE-301, a neurokinin 3-receptor antagonist for the treatment of vasomotor symptoms in menopausal women. The company is headquartered in Ann Arbor, Michigan.

Beat the Market (BTM) Rank^™

3.3 Analyst's Opinion

Consensus Rating
Millendo Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.60, and is based on 3 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $4.40, Millendo Therapeutics has a forecasted upside of 191.4% from its current price of $1.51.
Amount of Analyst Coverage
Millendo Therapeutics has only been the subject of 1 research reports in the past 90 days.

2.4 Community Rank

Outperform Votes
Millendo Therapeutics has received 74 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Millendo Therapeutics has received 79 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Millendo Therapeutics has received 51.63% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Millendo Therapeutics and other stocks. Vote “Outperform” if you believe MLND will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MLND will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Millendo Therapeutics does not currently pay a dividend.
Dividend Growth
Millendo Therapeutics does not have a long track record of dividend growth.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Millendo Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 3.70% of the stock of Millendo Therapeutics is held by insiders.
Percentage Held by Institutions
44.41% of the stock of Millendo Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3 Earnings and Valuation

Earnings Growth
Earnings for Millendo Therapeutics are expected to grow in the coming year, from ($2.13) to ($1.63) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Millendo Therapeutics is -0.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Millendo Therapeutics is -0.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Millendo Therapeutics has a P/B Ratio of 0.46. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.59 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:MLND

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.millendo.com

Phone734-845-9000

Employees37

Debt

Debt-to-Equity RatioN/A

Current Ratio5.36

Quick Ratio5.36

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$290,000.00

Price / Sales98.93

Cash FlowN/A

Price / Cash FlowN/A

Book Value$3.28 per share

Price / Book0.46

Profitability

EPS (Most Recent Fiscal Year)($3.25)

Net Income$-44,570,000.00

Net MarginsN/A

Return on Equity-92.03%

Return on Assets-72.69%

Miscellaneous

Outstanding Shares19,000,000

Market Cap$28.69 million

Next Earnings Date11/11/2020 (Estimated)

OptionableNot Optionable

$1.51

-0.11 (-6.79 %)

(As of 10/27/2020 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive MLND News and Ratings via Email

Sign-up to receive the latest news and ratings for MLND and its competitors with MarketBeat's FREE daily newsletter.

Millendo Therapeutics (NASDAQ:MLND) Frequently Asked Questions

How has Millendo Therapeutics' stock been impacted by Coronavirus (COVID-19)?

Millendo Therapeutics' stock was trading at $6.58 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, MLND stock has decreased by 77.1% and is now trading at $1.51.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Millendo Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Millendo Therapeutics in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Millendo Therapeutics.

When is Millendo Therapeutics' next earnings date?

Millendo Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, November 11th 2020.
View our earnings forecast for Millendo Therapeutics.

How were Millendo Therapeutics' earnings last quarter?

Millendo Therapeutics, Inc. (NASDAQ:MLND) issued its quarterly earnings data on Monday, August, 10th. The company reported ($0.56) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.55) by $0.01.
View Millendo Therapeutics' earnings history.

What price target have analysts set for MLND?

5 brokers have issued 12 month target prices for Millendo Therapeutics' stock. Their forecasts range from $2.00 to $6.00. On average, they anticipate Millendo Therapeutics' share price to reach $4.40 in the next twelve months. This suggests a possible upside of 191.4% from the stock's current price.
View analysts' price targets for Millendo Therapeutics.

Are investors shorting Millendo Therapeutics?

Millendo Therapeutics saw a increase in short interest in October. As of October 15th, there was short interest totaling 955,500 shares, an increase of 39.2% from the September 30th total of 686,400 shares. Based on an average daily trading volume, of 419,300 shares, the short-interest ratio is presently 2.3 days.
View Millendo Therapeutics' Short Interest.

Who are some of Millendo Therapeutics' key competitors?

Some companies that are related to Millendo Therapeutics include Corvus Pharmaceuticals (CRVS), Evoke Pharma (EVOK), Inflarx (IFRX), Equillium (EQ), Evolus (EOLS), Strongbridge Biopharma (SBBP), Oasmia Pharmaceutical AB (publ) (OASM), ObsEva (OBSV), Celyad Oncology (CYAD), Orgenesis (ORGS), Lantern Pharma (LTRN), Antibe Therapeutics (ATBPF), BetterLife Pharma (PVOTF), Zynerba Pharmaceuticals (ZYNE) and Chembio Diagnostics (CEMI).
View all competitors.

What other stocks do shareholders of Millendo Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Millendo Therapeutics investors own include Allena Pharmaceuticals (ALNA), Matinas BioPharma (MTNB), VYNE Therapeutics (VYNE), Acasti Pharma (ACST), Onconova Therapeutics (ONTX), TherapeuticsMD (TXMD), BioNano Genomics (BNGO), DURECT (DRRX), Geron (GERN) and Heat Biologics (HTBX).

Who are Millendo Therapeutics' key executives?

Millendo Therapeutics' management team includes the following people:

Dr. Julia C. Owens Ph.D., CEO, Pres & Director (Age 47, Pay $702.8k)
Mr. Louis J. Arcudi III, M.B.A., MBA, Chief Financial Officer (Age 59, Pay $495.79k)
Dr. Ryan Zeidan Ph.D., Chief Devel. Officer (Age 40, Pay $511.69k)
Ms. Tamara Lynn Joseph, Chief Legal Officer & Corp. Sec. (Age 57)
Mr. Thomas Hoover, Chief Bus. Officer
Dr. Christophe Arbet-Engels M.B.A., M.D., Ph.D., MBA, Chief Medical Officer (Age 58)

What is Millendo Therapeutics' stock symbol?

Millendo Therapeutics trades on the NASDAQ under the ticker symbol "MLND."

How do I buy shares of Millendo Therapeutics?

Shares of MLND can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Millendo Therapeutics' stock price today?

One share of MLND stock can currently be purchased for approximately $1.51.

How big of a company is Millendo Therapeutics?

Millendo Therapeutics has a market capitalization of $28.69 million and generates $290,000.00 in revenue each year. The company earns $-44,570,000.00 in net income (profit) each year or ($3.25) on an earnings per share basis. Millendo Therapeutics employs 37 workers across the globe.

What is Millendo Therapeutics' official website?

The official website for Millendo Therapeutics is www.millendo.com.

How can I contact Millendo Therapeutics?

Millendo Therapeutics' mailing address is 110 MILLER AVENUE SUITE 100, ANN ARBOR MI, 48104. The company can be reached via phone at 734-845-9000 or via email at [email protected]

This page was last updated on 10/28/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Get Started with MarketBeat

	Read Your Daily Newsletter
	Check Out My MarketBeat
	Watch Our Tutorial Videos
	Add a Stock to Your Watchlist
	Set Up an Instant Alert
	View a Company's Profile Page
	View Our Financial Calendars
	View Today's Analyst Ratings